Canandaigua National Bank & Trust Co. Acquires 84 Shares of Amgen Inc. (AMGN)
Canandaigua National Bank & Trust Co. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 1.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,219 shares of the medical research company’s stock after buying an additional 84 shares during the period. Canandaigua National Bank & Trust Co.’s holdings in Amgen were worth $1,098,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of AMGN. Oakworth Capital Inc. boosted its position in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares during the period. Delta Asset Management LLC TN boosted its position in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the period. Capital Advisors Ltd. LLC boosted its position in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares during the period. Vigilant Capital Management LLC boosted its position in shares of Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares during the period. Finally, Evanson Asset Management LLC acquired a new position in shares of Amgen during the second quarter worth about $211,000. 79.15% of the stock is owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.32% during mid-day trading on Monday, reaching $167.34. 2,514,609 shares of the company traded hands. Amgen Inc. has a 52 week low of $138.06 and a 52 week high of $176.85. The firm has a 50-day moving average price of $171.51 and a 200 day moving average price of $161.44. The firm has a market capitalization of $125.23 billion, a price-to-earnings ratio of 17.12 and a beta of 0.94.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.58 billion. During the same quarter in the prior year, the company earned $2.57 EPS. Amgen’s quarterly revenue was up 5.9% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post $11.36 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were issued a $1.00 dividend. The ex-dividend date was Monday, August 15th. This represents a $4.00 annualized dividend and a yield of 2.39%. Amgen’s dividend payout ratio (DPR) is presently 40.90%.
A number of research analysts recently issued reports on AMGN shares. BMO Capital Markets reissued a “buy” rating and set a $186.00 price target on shares of Amgen in a research report on Tuesday, July 12th. Vetr raised shares of Amgen from a “sell” rating to a “hold” rating and set a $165.78 price target for the company in a research report on Wednesday, July 27th. Leerink Swann reissued a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Zacks Investment Research cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Monday, August 1st. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and set a $206.00 price target (up from $204.00) on shares of Amgen in a research report on Tuesday, September 27th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $185.06.
In related news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.20% of the stock is currently owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.